Study examines cannabidiol's effect on simulated driving Cannabidiol CBD Driving DUI AJPMFocus WestVirginiaU
By Dr. Chinta SidharthanNov 29 2022Reviewed by Benedette Cuffari, M.Sc. In a recent study published in AJPM Focus, researchers discuss the results of a randomized pilot clinical trial using simulated driving performance to investigate whether drowsiness induced by the medical use of cannabidiol had an impact on safe driving.
One of the known side effects of cannabidiol is drowsiness. While various placebo-controlled clinical trials have investigated the effectiveness of cannabidiol in clinical populations with neuropsychiatric and neurological problems, limited studies have explored the effects of non-prescription cannabidiol on activities such as driving.
All participants were required to complete a demographic survey and various cognitive and psychomotor tests. They were then randomly allocated to the cannabidiol treatment or placebo group. Time spent driving beyond the shoulder or centerline of the roadway was the second primary outcome. The total number of collisions, time to the first collision, and mean brake reaction time were the third, fourth, and fifth primary outcomes, respectively.
The authors believe that though not significant, the study findings indicate the need for caution. Participants in the treatment group performed slightly worse along all primary and secondary outcomes as compared to those in the placebo group. Drivers who are impaired generally have slower reaction times, as well as difficulty maintaining speed and staying within lanes.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Phase IIb Randomized, Placebo-Controlled, Dose-Escalating, Double-Blind Study of Cannabidiol Oil for the Relief of Symptoms in Advanced Cancer (MedCan1-CBD) | Journal of Clinical OncologyPURPOSE To determine whether cannabidiol (CBD) oil can improve symptom distress in patients with advanced cancer receiving palliative care. METHODS Participants were adults with advanced cancer and symptom distress (Edmonton Symptom Assessment Scale [ESAS] total score of ≥ 10/90) who received titrated CBD oil 100 mg/mL, 0.5 mL once daily to 2 mL three times a day, or matched placebo for 28 days. The primary outcome was ESAS total symptom distress score (TSDS) at day 14. Response was defined as a decrease in TSDS by ≥ 6 at day 14. Secondary outcomes were ESAS TSDS over time, individual symptom scores, patient-determined effective dose, opioid use, Global Impression of Change, depression, anxiety, quality of life, and adverse events. RESULTS Of the 144 patients randomly assigned, the planned sample size of 58 participants on CBD and 63 on placebo reached the primary analysis point (day 14). The unadjusted change in TSDS from baseline to day 14 was –6.2 (standard deviation, 14.5) for placebo and –3.0 (standard deviation, 15.2) for CBD with no significant difference between arms (P=.24). Similarly, there was no detected difference in proportion of responders (placebo: 37 of 63 [58.7%], CBD: 26 of 58 [44.8%], P=.13). All components of ESAS improved (fell) over time with no difference between arms. The median dose of participant-selected CBD was 400 mg per day with no correlation with opioid dose. There was no detectable effect of CBD on quality of life, depression, or anxiety. Adverse events did not differ significantly between arms apart from dyspnea that was more common with CBD. Most participants reported feeling better or much better at days 14 (53% CBD and 65% placebo) and 28 (70% CBD and 64% placebo). CONCLUSION CBD oil did not add value to the reduction in symptom distress provided by specialist palliative care alone.
Read more »
Researchers use a comparative study to model RSV prevention in childrenUsing computational modeling, a new paper compares the benefit of maternal vaccines versus the administration of respiratory syncytial virus (RSV)-specific monoclonal antibody (mAb) therapy against RSV.
Read more »
What genes are associated with asthma exacerbations?In a new study, researchers reviewed the genomics, transcriptomics, and epigenetics of asthma exacerbations (AEs).
Read more »
Cannabidiol and the shifting perspective of epilepsy drug discoveryCannabidiol and the shifting perspective of epilepsy drug discovery Cannabidiol Medicine Research Anticonvulsant Cannabis DrugDiscovery Epilepsy Neurology UW
Read more »
Researchers propose the tools and frameworks of EBM+ to help overcome the COVID-19 pandemicResearchers propose the tools and frameworks of EBM+ to help overcome the COVID-19 pandemic bmj_company UniofOxford UofT UNSW COVID19 coronavirus covid pandemic medicine evidencebasedmedicine
Read more »
Twitter search spam campaign hides China riots, researchers sayElon Musk meanwhile muses whether Apple 'hate[s] free speech in America' because the company mostly stopped advertising on Twitter
Read more »